Skip to main content
Toggle navigation
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Red Recording
Sig Meeting
Like
Tweet
Print
Angad Chhabra, BS
Axsome Therapeutics, Inc.
Poster(s):
(T 19) Symbravo® (MoSEIC(TM) meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Return to Function Endpoint Analysis from MOMENTUM
(T 30) Symbravo® (MoSEIC(TM) Meloxicam and Rizatriptan) for the Treatment of Migraine: Sustained Pain Relief and Pain Freedom Among 2-Hour Responders in the Phase 3 MOMENTUM and MOVEMENT Trials
(T 33) Symbravo® (MoSEIC(TM) meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Safety Endpoint Analysis of INTERCEPT and MOMENTUM
